Equities Research Analysts’ Updated EPS Estimates for November 25th (AAPL, ABEO, ASRT, AVXL, AXSM, BBWI, BCOV, BERY, CRWD, CURV)

Equities Research Analysts’ updated eps estimates for Monday, November 25th:

Apple (NASDAQ:AAPL) had its overweight rating reissued by analysts at Morgan Stanley. They currently have a $273.00 target price on the stock.

Abeona Therapeutics (NASDAQ:ABEO) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $15.00 price target on the stock.

Assertio (NASDAQ:ASRT) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $4.00 target price on the stock.

Anavex Life Sciences (NASDAQ:AVXL) had its buy rating reaffirmed by analysts at D. Boral Capital. They currently have a $46.00 target price on the stock.

Axsome Therapeutics (NASDAQ:AXSM) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $180.00 price target on the stock.

Bath & Body Works (NYSE:BBWI) had its outperform rating reiterated by analysts at Telsey Advisory Group. Telsey Advisory Group currently has a $42.00 price target on the stock.

Brightcove (NASDAQ:BCOV) had its neutral rating reiterated by analysts at Rosenblatt Securities. The firm currently has a $4.45 target price on the stock, down from their previous target price of $5.00.

Berry Global Group (NYSE:BERY) had its neutral rating reissued by analysts at Citigroup Inc.. They currently have a $76.00 price target on the stock.

Berry Global Group (NYSE:BERY) had its overweight rating reaffirmed by analysts at JPMorgan Chase & Co.. The firm currently has a $76.00 price target on the stock, up from their previous price target of $70.00.

CrowdStrike (NASDAQ:CRWD) had its hold rating reaffirmed by analysts at Westpark Capital.

Torrid (NYSE:CURV) had its market perform rating reissued by analysts at Telsey Advisory Group. Telsey Advisory Group currently has a $8.00 price target on the stock.

e.l.f. Beauty (NYSE:ELF) had its buy rating reaffirmed by analysts at DA Davidson. DA Davidson currently has a $170.00 target price on the stock.

Emera (TSE:EMA) was upgraded by analysts at Bank of America Co. from a neutral rating to a buy rating. The firm currently has C$57.00 price target on the stock, up from their previous price target of C$55.00.

EQB (TSE:EQB) had its price target boosted by Scotiabank from C$109.00 to C$135.00.

Gain Therapeutics (NASDAQ:GANX) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $8.00 target price on the stock.

Imunon (NASDAQ:IMNN) had its buy rating reissued by analysts at D. Boral Capital. They currently have a $29.00 target price on the stock.

Jamieson Wellness (TSE:JWEL) had its target price raised by National Bankshares, Inc. from C$36.50 to C$42.00.

RediShred Capital (CVE:KUT) had its price target cut by Ventum Financial from C$7.00 to C$5.00.

Laurentian Bank of Canada (TSE:LB) had its target price raised by Scotiabank from C$26.00 to C$30.00.

Lexaria Bioscience (NASDAQ:LEXX) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $10.00 price target on the stock.

Longeveron (NASDAQ:LGVN) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $10.00 price target on the stock.

LivaNova (NASDAQ:LIVN) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $75.00 target price on the stock.

Mastercard (NYSE:MA) had its outperform rating reissued by analysts at William Blair.

MAG Silver (TSE:MAG) (NYSEAMERICAN:MAG) had its target price raised by Stifel Nicolaus from C$25.00 to C$25.50.

Meta Platforms (NASDAQ:META) had its strong-buy rating reiterated by analysts at Raymond James. They currently have a $675.00 price target on the stock.

Marsh & McLennan Companies (NYSE:MMC) had its outperform rating reaffirmed by analysts at Evercore ISI. They currently have a $242.00 target price on the stock.

National Bank of Canada (TSE:NA) had its price target raised by Scotiabank from C$129.00 to C$154.00.

Neurogene (NASDAQ:NGNE) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $55.00 price target on the stock.

NRx Pharmaceuticals (NASDAQ:NRXP) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $19.00 target price on the stock.

Oruka Therapeutics (NASDAQ:ORKA) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $45.00 target price on the stock.

Palatin Technologies (NYSEAMERICAN:PTN) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $17.00 target price on the stock.

RAPT Therapeutics (NASDAQ:RAPT) had its neutral rating reaffirmed by analysts at HC Wainwright.

Cartesian Therapeutics (NASDAQ:RNAC) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $41.00 price target on the stock.

Royal Bank of Canada (TSE:RY) (NYSE:RY) had its target price raised by Scotiabank from C$167.00 to C$197.00.

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $69.00 price target on the stock.

Suncor Energy (TSE:SU) (NYSE:SU) was given a C$69.00 price target by analysts at Gerdes Energy Research. The firm currently has a buy rating on the stock.

Summit Materials (NYSE:SUM) had its sector perform rating reiterated by analysts at Royal Bank of Canada. They currently have a $52.50 price target on the stock, down from their previous price target of $54.00.

Summit Materials (NYSE:SUM) had its neutral rating reiterated by analysts at JPMorgan Chase & Co.. JPMorgan Chase & Co. currently has a $52.50 target price on the stock, up from their previous target price of $43.00.

Toronto-Dominion Bank (TSE:TD) (NYSE:TD) had its target price increased by Scotiabank from C$86.00 to C$98.00.

Target (NYSE:TGT) had its outperform rating reaffirmed by analysts at Oppenheimer Holdings Inc.. Oppenheimer Holdings Inc. currently has a $165.00 target price on the stock.

Tenaya Therapeutics (NASDAQ:TNYA) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $18.00 target price on the stock.

Viridian Therapeutics (NASDAQ:VRDN) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $38.00 price target on the stock.

Workday (NASDAQ:WDAY) had its buy rating reaffirmed by analysts at Needham & Company LLC. Needham & Company LLC currently has a $300.00 price target on the stock.

XOS (NASDAQ:XOS) had its market perform rating reissued by analysts at Northland Securities. The firm currently has a $5.00 price target on the stock, down from their previous price target of $9.00.